Results 171 to 180 of about 12,533 (219)

Development of Acellular Pertussis Vaccines

Biologicals, 1999
In 1974, the authors reported the isolation and characterization of protective antigens of Bordetella pertussis in mice. With this information, an acellular pertussis vaccine was developed, composed mainly of pertussis toxin (PT) and filamentous haemagglutinin (FHA).
Y, Sato, H, Sato
openaire   +2 more sources

Acellular Pertussis Vaccines for Infants

New England Journal of Medicine, 1996
Whole-cell vaccines, which are suspensions of killed Bordetella pertussis organisms, are among our most effective and least satisfactory vaccines.
K M, Edwards, M D, Decker
openaire   +2 more sources

Standardization of Acellular Pertussis Vaccines

Biologicals, 1999
In comparison with the current whole cell pertussis vaccine, the new generation of acellular pertussis vaccines opens new opportunities to improve the standardization of the product, because well defined and characterized components are used in these new products.However, different compositions, purification and inactivation methods are used by ...
openaire   +2 more sources

Combination vaccines consisting of acellular pertussis vaccines

The Pediatric Infectious Disease Journal, 1997
Combination vaccines consisting of multiple vaccine antigens delivered in a single injection simplify vaccine administration. Combining multiple antigens into one injection, however, presupposes that the administration of multiple vaccines in combination will not reduce the safety and immunogenicity of the component vaccines.
K M, Edwards, M D, Decker
openaire   +2 more sources

[Acellular pertussis vaccine].

Wiener medizinische Wochenschrift (1946), 1991
Acellular pertussis vaccines contain antigen components of B. pertussis, usually lymphocytosis promoting factor (LPF) which is also called pertussis-toxin (PT) or pertussigen, filamentous hemagglutinin (FH) and, eventually, agglutinogens 2 and 3. Acellular vaccines are being used in Japan since 1981.
G, Wiedermann, F, Ambrosch, H, Vanura
openaire   +1 more source

[Acellular pertussis vaccines].

Immunitat und Infektion, 1993
Each vaccine is normally rated according to its efficacy and to the frequency and severity of unwanted side effects. The efficacy of whole-cell pertussis vaccines is beyond doubt, its frequent side effects, however, stimulated research into less reactogenic acellular vaccines.
H, Finger, C H, Wirsing von König
openaire   +1 more source

Potency testing of acellular pertussis vaccines

Vaccine, 1992
The laboratory assessment of the potential of acellular pertussis vaccines to protect against human disease is a major problem. The mouse intracerebral challenge test, which is the accepted potency assay for whole cell pertussis vaccines, is not suitable for testing acellular vaccines, and more recently developed murine respiratory infection assays ...
A, Robinson, S G, Funnell
openaire   +2 more sources

Whole-Cell and Acellular Pertussis Vaccines

Annals of Pharmacotherapy, 1994
OBJECTIVE: To provide a review of pertussis vaccines, including information on efficacy, adverse reactions, and antibody production following administration of both whole-cell and acellular pertussis vaccines. DATA SOURCES: A MEDLINE search and extensive review of journals was conducted to identify the information for this review.
S M, Wintermeyer, M C, Nahata, K S, Kyllonen   +2 more
openaire   +2 more sources

The Efficacy of Acellular Pertussis Vaccine

JAMA: The Journal of the American Medical Association, 1989
To the Editor.— Reporting from a workshop at the National Institutes of Health, Bethesda, Md, 1 Mr Marwick stated that "the large Swedish field trial of two acellular pertussis vaccines 2 has not shown levels of efficacy high enough to make either vaccine a likely candidatefor immediate licensure in the United States." We can now report efficacy data ...
P, Olin, J, Storsaeter, V, Romanus
openaire   +2 more sources

Protective effect of acellular pertussis vaccines

European Journal of Clinical Microbiology & Infectious Diseases, 1988
Two acellular pertussis vaccines, a mono-component toxoid of pertussis toxin and a two-component vaccine containing both the toxoid and filamentous haemagglutinin, were used for primary immunization of infants 5 1/2 to 10 months of age in two clinical trials in Sweden. Over a follow-up period of 12 to 17 months, 37 children were exposed to pertussis in
M, Blennow, S, Hedenskog, M, Granström
openaire   +2 more sources